Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2016-10-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Quarterly Activities Report and Appendix 4C 6 pages 723.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT (ASX : BD1) FOR THE PERIOD ENDING 30 SEPTEMBER 2016' and contains detailed financial data including consolidated statements of cash flows, cash equivalents, payments to directors, financing facilities, estimated cash outflows, and compliance statements. It references compliance with Listing Rule 4.7B and Australian Accounting Standards. The length of the document (10,583 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive financial report for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). Q1 2016
2016-10-30 English
Annual Report to Shareholders 48 pages 1.2MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2016' and contains a detailed table of contents including Directors' Report, Corporate Governance Statement, Auditor's Independence Statement, and full financial statements such as Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows, Notes to Financial Statements, Shareholders' Information, and Independent Auditor's Report. The text includes detailed information about directors, principal activities, operating results, corporate structure, and financial position for the year ended 30 June 2016. The length of the document is substantial (15,000 characters), indicating it is the full report rather than an announcement. The presence of comprehensive financial data and management discussion confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2016
2016-10-18 English
Appendix 4G 11 pages 227.7KB
Governance Information Classification · 95% confidence The document is an Appendix 4G filing related to corporate governance disclosures for Bard1 Life Sciences Limited for the financial year ended 30 June 2016. It references compliance with ASX Listing Rules 4.7.3 and 4.10.3, which require lodging a corporate governance statement alongside the annual report. The content includes detailed disclosures about the company's adherence to the ASX Corporate Governance Council Principles and Recommendations, explanations for any non-compliance, and references to the corporate governance statement included in the annual report. This type of document is specifically focused on governance practices and compliance disclosures rather than financial results or management changes. It is not the annual report itself but a regulatory filing related to governance disclosures. Given the detailed governance content and the nature of Appendix 4G, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed governance content support this classification with high confidence.
2016-10-18 English
Notice of Annual General Meeting/Proxy Form 15 pages 715.8KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes detailed information about the meeting date, location, voting procedures, proxy forms, and agenda items. It references the Annual Financial Statements for the year ended 30 June 2016, the Directors' Report, the Auditors' Report, and includes resolutions such as the adoption of the Remuneration Report and re-election of a director. The document also contains an Explanatory Statement providing additional information for shareholders to make informed voting decisions. The content is typical of a formal notice sent to shareholders prior to an AGM, including proxy instructions and voting eligibility, rather than the actual AGM materials or minutes. It does not contain the full Annual Report or financial statements themselves but rather the notice and explanatory materials for the meeting. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and explanatory statements.
2016-10-06 English
Statutory Audited Financial Statements 39 pages 1.3MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'AUDITED FINANCIAL STATEMENTS For the six months ended 30 June 2016' and includes a Directors' Report, detailed financial and corporate information, and auditor details. It covers a six-month period ending 30 June 2016, indicating it is a half-year financial report. The content includes financial results, corporate structure, directors' details, share information, and remuneration report, all typical of an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2016
2016-09-29 English
Company Update - Promising Result for Ovarian Cancer 2 pages 226.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing promising research results related to ovarian cancer detection by BARD1 Life Sciences Limited. It discusses preliminary research findings, scientific background, and future plans for product development. There is no indication of financial data, regulatory filings, shareholder information, or formal report content such as annual or quarterly financial statements. The document is a corporate announcement of research progress rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) since it is a company announcement that does not fit other specific categories.
2016-09-21 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.